RIPK3—a predictive marker for personalized immunotherapy?

Cancer immunotherapy is an attractive therapeutic option but it is currently unclear which patient may benefit from such approaches. Using the model of cervical cancer, we have demonstrated that PolyIC-driven immunogenicity strictly depends on the necroptosis regulator RIPK3 in the neoplastic cells....

Descripción completa

Detalles Bibliográficos
Autor principal: Smola, Sigrun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839344/
https://www.ncbi.nlm.nih.gov/pubmed/27141374
http://dx.doi.org/10.1080/2162402X.2015.1075695
_version_ 1782428127359664128
author Smola, Sigrun
author_facet Smola, Sigrun
author_sort Smola, Sigrun
collection PubMed
description Cancer immunotherapy is an attractive therapeutic option but it is currently unclear which patient may benefit from such approaches. Using the model of cervical cancer, we have demonstrated that PolyIC-driven immunogenicity strictly depends on the necroptosis regulator RIPK3 in the neoplastic cells. This proposes RIPK3 as a novel predictive marker for personalization of cancer immunotherapy
format Online
Article
Text
id pubmed-4839344
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-48393442016-05-02 RIPK3—a predictive marker for personalized immunotherapy? Smola, Sigrun Oncoimmunology Author's View Cancer immunotherapy is an attractive therapeutic option but it is currently unclear which patient may benefit from such approaches. Using the model of cervical cancer, we have demonstrated that PolyIC-driven immunogenicity strictly depends on the necroptosis regulator RIPK3 in the neoplastic cells. This proposes RIPK3 as a novel predictive marker for personalization of cancer immunotherapy Taylor & Francis 2015-08-24 /pmc/articles/PMC4839344/ /pubmed/27141374 http://dx.doi.org/10.1080/2162402X.2015.1075695 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Smola, Sigrun
RIPK3—a predictive marker for personalized immunotherapy?
title RIPK3—a predictive marker for personalized immunotherapy?
title_full RIPK3—a predictive marker for personalized immunotherapy?
title_fullStr RIPK3—a predictive marker for personalized immunotherapy?
title_full_unstemmed RIPK3—a predictive marker for personalized immunotherapy?
title_short RIPK3—a predictive marker for personalized immunotherapy?
title_sort ripk3—a predictive marker for personalized immunotherapy?
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839344/
https://www.ncbi.nlm.nih.gov/pubmed/27141374
http://dx.doi.org/10.1080/2162402X.2015.1075695
work_keys_str_mv AT smolasigrun ripk3apredictivemarkerforpersonalizedimmunotherapy

Ejemplares similares